Biotech

Bristol Myers Squibb (NYSE: BMY) today announced that the company will participate in a fireside chat at the 7 th Annual Virtual Truist Life Sciences Summit, which will be webcast on Wednesday, May 5, 2021. Adam Lenkowsky, Senior Vice President, General Manager of U.S. Oncology, Immunology and CV and Winselow Tucker, Senior Vice President, General Manager, U.S. Hematology will answer questions about the company at 8 a.m. ET.

Investors and the general public are invited to listen to a live webcast of the session at http://investor.bms.com . An archived edition of the session will be available later that day.

About Bristol Myers Squibb

Bristol Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. For more information about Bristol Myers Squibb, visit us at BMS.com or follow us on LinkedIn , Twitter , YouTube , Facebook , and Instagram .

corporatefinancial-news

Bristol Myers Squibb

Media:
media@bms.com

Investor Relations:
Tim Power
609-252-7509
timothy.power@bms.com

Nina Goworek
908-673-9711
nina.goworek@bms.com

News Provided by Business Wire via QuoteMedia

Lawsuits Filed Against ABBV, RSKD and ARQQ - Jakubowitz Law Pursues Shareholders Claims

Jakubowitz Law announces that securities fraud class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies who purchased shares within the class periods listed below. Shareholders interested in representing the class of wronged shareholders have until the lead plaintiff deadline to petition the court. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. For more details and to speak with our firm without cost or obligation, follow the links below

ABBVie Inc. (NYSE:ABBV)

News Provided by ACCESSWIRE IA via QuoteMedia

Keep reading...Show less

The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of AUPH, LILM and LICY

The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. There is no cost to participate in the suit. If you suffered a loss, you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff

Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH)
Class Period: May 7, 2021 - February 25, 2022
Lead Plaintiff Deadline: June 14, 2022

News Provided by ACCESSWIRE IA via QuoteMedia

Keep reading...Show less

The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of VRT, VLTA and ABBV

The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. There is no cost to participate in the suit. If you suffered a loss, you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff

Vertiv Holdings Co (NYSE:VRT)
This lawsuit is on behalf of persons and entities that: (a) purchased or otherwise acquired Vertiv securities between February 24, 2021, and February 23, 2022, inclusive; and/or (b) purchased Vertiv shares in or traceable to the Company's secondary public offering of Class A common stock conducted on or around November 4, 2021.
Lead Plaintiff Deadline: May 23, 2022

News Provided by ACCESSWIRE IA via QuoteMedia

Keep reading...Show less

AbbVie Submits New Drug Application to U.S. FDA for Investigational ABBV-951 for the Treatment of Advanced Parkinson's Disease

  • If approved, ABBV-951 will offer patients the first continuous subcutaneous delivery of carbidopa/levodopa prodrugs
  • Submission is supported by Phase 3 study that demonstrated patients had significant increases in hours of "On" time without troublesome dyskinesia, compared to oral immediate-release carbidopa/levodopa

ABBVie (NYSE: ABBV) today announced that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for ABBV-951 (foscarbidopafoslevodopa) for the treatment of motor fluctuations in patients with advanced Parkinson's disease (PD).

The submission is based on results from a Phase 3, head-to-head, randomized and controlled clinical trial demonstrating statistically significant improvement in "On" time without troublesome dyskinesia compared to oral immediate-release carbidopa/levodopa (CD/LD).

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less

Lawsuits Filed Against Vrt, Abbv And Ibm - Jakubowitz Law Pursues Shareholders Claims

Jakubowitz Law announces that securities fraud class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies who purchased shares within the class periods listed below. Shareholders interested in representing the class of wronged shareholders have until the lead plaintiff deadline to petition the court. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. For more details and to speak with our firm without cost or obligation, follow the links below

Vertiv Holdings Co (NYSE:VRT)

News Provided by ACCESSWIRE IA via QuoteMedia

Keep reading...Show less

The Gross Law Firm Announces Class Actions on Behalf of Shareholders of VLTA, AUPH and BKKT

The securities litigation law firm of The Gross Law Firm issues the following notice on behalf of shareholders in the following publicly traded companies. Shareholders who purchased shares in the following companies during the dates listed are encouraged to contact the firm regarding possible Lead Plaintiff appointment. Appointment as Lead Plaintiff is not required to partake in any recovery

Volta Inc. (NYSE:VLTA)

News Provided by ACCESSWIRE IA via QuoteMedia

Keep reading...Show less

Latest Press Releases

Related News

×